NASDAQ:SYRS Syros Pharmaceuticals (SYRS) Stock Price, News & Analysis $0.0016 +0.00 (+33.33%) As of 08/1/2025 03:52 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Syros Pharmaceuticals Stock (NASDAQ:SYRS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Syros Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.0012▼$0.002250-Day Range$0.00▼$0.0352-Week Range$0.00▼$0.10Volume6,723 shsAverage Volume213,055 shsMarket Capitalization$42.93 thousandP/E RatioN/ADividend YieldN/APrice Target$3.33Consensus RatingHold Company Overview Syros Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors. The company was formerly known as LS22, Inc. and changed its name to Syros Pharmaceuticals, Inc. in August 2012. Syros Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Cambridge, Massachusetts. Read More Syros Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks80th Percentile Overall ScoreSYRS MarketRank™: Syros Pharmaceuticals scored higher than 80% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.1 / 5Analyst RatingHold Consensus RatingSyros Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on 1 buy rating, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageSyros Pharmaceuticals has received no research coverage in the past 90 days.Read more about Syros Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Syros Pharmaceuticals are expected to decrease in the coming year, from ($2.94) to ($2.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Syros Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Syros Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSyros Pharmaceuticals has a P/B Ratio of 0.00. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.40% of the outstanding shares of Syros Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyros Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Syros Pharmaceuticals has recently decreased by 9.13%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSyros Pharmaceuticals does not currently pay a dividend.Dividend GrowthSyros Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.3 / 5Environmental Score-0.88 Percentage of Shares Shorted0.40% of the outstanding shares of Syros Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverSyros Pharmaceuticals has a short interest ratio ("days to cover") of 0.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Syros Pharmaceuticals has recently decreased by 9.13%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News SentimentN/A MarketBeat FollowsOnly 3 people have added Syros Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Syros Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.26% of the stock of Syros Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions91.47% of the stock of Syros Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Syros Pharmaceuticals' insider trading history. Receive SYRS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Syros Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address SYRS Stock News HeadlinesSyros Pharmaceuticals, Inc. (NASDAQ:SYRS) Receives Consensus Rating of "Hold" from BrokeragesJuly 26, 2025 | americanbankingnews.comRege Nephro buys Tamibarotene-related assets from Syros PharmaceuticalsApril 15, 2025 | msn.comThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important updates you'll ever see. A new initiative, linked to President Trump's Executive Order #14196, has the potential to do more than just protect Social Security from collapse... According to renowned investor Louis Navellier, it could increase benefits by as much as 400%.August 2 at 2:00 AM | InvestorPlace (Ad)Syros Pharmaceuticals trading resumesMarch 1, 2025 | markets.businessinsider.comSyros Pharmaceuticals Plans to Wind Down OperationsMarch 1, 2025 | marketwatch.comSyros Pharmaceuticals voluntarily delists from Nasdaq, deregisters common stockMarch 1, 2025 | markets.businessinsider.comSyros Announces Voluntary Delisting from Nasdaq and SEC DeregistrationFebruary 28, 2025 | businesswire.comSyros Pharmaceuticals stock hits 52-week low at $0.18 amid steep declineJanuary 29, 2025 | msn.comSee More Headlines SYRS Stock Analysis - Frequently Asked Questions How have SYRS shares performed this year? Syros Pharmaceuticals' stock was trading at $0.2298 on January 1st, 2025. Since then, SYRS stock has decreased by 99.3% and is now trading at $0.0016. How were Syros Pharmaceuticals' earnings last quarter? Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) released its quarterly earnings data on Thursday, October, 31st. The company reported ($0.68) EPS for the quarter, topping analysts' consensus estimates of ($0.76) by $0.08. Read the conference call transcript. When did Syros Pharmaceuticals' stock split? Syros Pharmaceuticals's stock reverse split before market open on Monday, September 19th 2022.The 1-10 reverse split was announced on Monday, September 19th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, September 19th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. When did Syros Pharmaceuticals IPO? Syros Pharmaceuticals (SYRS) raised $60 million in an initial public offering on Thursday, June 30th 2016. The company issued 4,000,000 shares at $14.00-$16.00 per share. Cowen and Company and Piper Jaffray served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers. Who are Syros Pharmaceuticals' major shareholders? Top institutional investors of Syros Pharmaceuticals include FNY Investment Advisers LLC. Insiders that own company stock include Jason Haas, Conley Chee, Timothy Tyson, David Roth, Richard A Young, Eric R Olson and Nancy A Simonian. View institutional ownership trends. How do I buy shares of Syros Pharmaceuticals? Shares of SYRS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Syros Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Syros Pharmaceuticals investors own include Salesforce (CRM), QUALCOMM (QCOM), Bank of America (BAC), Bristol Myers Squibb (BMY), Pfizer (PFE), Twilio (TWLO) and AbbVie (ABBV). Company Calendar Last Earnings10/31/2024Today8/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SYRS CIK1556263 Webwww.syros.com Phone(617) 744-1340FaxN/AEmployees120Year FoundedN/APrice Target and Rating Average Price Target for Syros Pharmaceuticals$3.33 High Price Target$5.00 Low Price Target$1.00 Potential Upside/Downside+208,233.3%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($3.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$164.57 million Net MarginsN/A Pretax Margin-25,275.20% Return on Equity-3,369.56% Return on Assets-97.04% Debt Debt-to-Equity RatioN/A Current Ratio2.25 Quick Ratio2.25 Sales & Book Value Annual Sales$386 thousand Price / Sales0.11 Cash FlowN/A Price / Cash FlowN/A Book Value$0.79 per share Price / Book0.00Miscellaneous Outstanding Shares26,832,000Free Float23,542,000Market Cap$42.93 thousand OptionableOptionable Beta1.31 Social Links The Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free Report This page (NASDAQ:SYRS) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Syros Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Syros Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.